In a large study of 400 people with HIV-related belly fat, tesamorelin reduced visceral fat by nearly 11% after 6 months, compared to less than 1% in the placebo group, and also reduced waist and trunk fat while increasing IGF-1 levels.

Scientific Claim

In a randomized, double-blind, placebo-controlled trial of 404 HIV-infected patients with abdominal fat accumulation, tesamorelin reduced visceral adipose tissue by 10.9% (21 cm²) after 6 months compared to less than 1% in the placebo group, with concurrent reductions in waist circumference and trunk fat and increases in IGF-I levels.

Original Statement

“The reason that we know so much about it and its fat loss effects is because it's been studied extensively in very specific populations. Okay? Originally they had looked at it a lot with people who had HIV who develop excess visceral fat and then lose muscle. So one of the most important studies here was published in 2010 like way back 15 years ago in the journal of acquired immune deficiency syndromes. So researchers recruited 400 individuals with excess visceral fat and followed them for a full year. So for the first 6 months participants received either tessamarellin or a placebo. But here's what happened. It was pretty interesting. Visceral fat decreased by nearly 11% in the tesarellan group. Okay, this was compared to less than 1% in the placebo group. Waist circumference went down, trunk fat went down, IGF levels went up, and that IGF one piece matters a lot. We'll come back to that.”

From video:The Most Powerful Peptide for Visceral Belly Fat has Been ReleasedbyThomas DeLauer

Context Details

Domain

pharmacology

Population

human

Subject

tesamorelin

Action

reduces

Target

visceral adipose tissue by 10.9% after 6 months in HIV patients with abdominal fat accumulation

Intervention Details

Type: drug

Dosage: 2 mg SC daily

Duration: 6 months

Evidence from Studies

Supporting (3)

Unknown Title

Randomized Controlled Trial

Human

This study found that a drug called tesamorelin helped HIV patients lose belly fat without harming their blood sugar, and it worked much better than a placebo.

1499. Tesamorelin Reduces Visceral Adipose Tissue and Liver Fat in INSTI-Treated Persons with HIV

Randomized Controlled Trial

Human

This study shows that tesamorelin helps reduce belly fat in people with HIV, which matches the claim.

Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV

Randomized Controlled Trial

Human

2017 Oct 23

Tesamorelin not only reduces belly fat but also improves liver health in people with HIV.

Contradicting (0)

No contradicting evidence found

Similar Assertions

A hormone treatment called tesamorelin decreases belly fat by 42 square centimeters more than a placebo in people with HIV who have excess abdominal fat after six months of treatment.

95%

A drug called tesamorelin helps HIV patients with belly fat buildup lose about 11% of their dangerous internal belly fat in six months, while those on a dummy pill lose almost none.

94%

A drug called tesamorelin helps reduce belly fat deep inside the abdomen for people with HIV who are on medication, making their belly fat decrease by about 15% compared to those not taking the drug. This finding is from the abstract summary - full study details were not available

94%

Continuing tesamorelin for a full year helps HIV patients with belly fat lose nearly 18% of their dangerous internal belly fat, with no loss of benefit over time.

93%

A hormone treatment called tesamorelin doesn't change the fat under the skin in people with HIV who have excess belly fat after six months of treatment.

92%